Atara CFO/COO Eric Hyllengren to depart March 31; Yanina Grant-Huerta named CAO

Atara Biotherapeutics, Inc.

CFO/COO Eric Hyllengren's employment ends March 31, 2025; he will provide consulting through July 31 at an hourly rate.
Hyllengren receives severance including 2024 bonus; he relinquishes all vested and unvested stock option awards.
Yanina Grant-Huerta appointed Chief Accounting Officer and principal accounting officer effective March 31; she was VP of FP&A since March 2023.
Grant-Huerta previously spent 13 years at Amgen; no family relationships or related-party transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eric Hyllengren

Chief Financial Officer and Chief Operating Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2025-03-31
Filed: March 31, 2025, 7:59 PM ET

On March 25, 2025, it was agreed that the employment of Eric Hyllengren, the Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. (the “ Company ”), would end effective March 31, 2025.

Appointed

Yanina Grant-Huerta

Chief Accounting Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2025-03-31
Filed: March 31, 2025, 7:59 PM ET

On March 31, 2025, the Company appointed Yanina Grant-Huerta as the Company’s Chief Accounting Officer and principal accounting officer, effective March 31, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Hyllengren departed as Chief Financial Officer and Chief Operating Officer at Atara Biotherapeutics, Inc..

Action: ended
Role: Chief Financial Officer and Chief Operating Officer

Exact text from the filing

On March 25, 2025, it was agreed that the employment of Eric Hyllengren, the Chief Financial Officer and Chief Operating Officer of Atara Biotherapeutics, Inc. (the “ Company ”), would end effective March 31, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Yanina Grant-Huerta was appointed as Chief Accounting Officer at Atara Biotherapeutics, Inc..

Action: appointed
Role: Chief Accounting Officer

Exact text from the filing

On March 31, 2025, the Company appointed Yanina Grant-Huerta as the Company’s Chief Accounting Officer and principal accounting officer, effective March 31, 2025.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-068789

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.